Kerala Restricts Child Medicine Sales
Analysis based on 6 articles · First reported Oct 06, 2025 · Last updated Oct 06, 2025
The regulatory actions by India — Kerala, including the suspension of Coldrif syrup sales and the new prescription directive, could negatively impact pharmaceutical companies operating in India, particularly those manufacturing cough syrups. This event highlights increased scrutiny on drug safety, potentially leading to broader regulatory changes across the Indian pharmaceutical market.
The India — Kerala Health Department has issued a directive prohibiting the sale of medicines to children under 12 without a doctor's prescription, prompted by concerns over certain cough syrups. Health Minister Veena George announced the formation of a three-member expert panel, including the Indian Academy of Pediatrics, to formulate new guidelines on cough syrup use. This action follows reports of issues with the SR-13 batch of Coldrif syrup, which was distributed in India — Tamil Nadu, India — Odisha, India — Madhya Pradesh, and India — Puducherry, and problems with another cough syrup in India — Rajasthan. The sale of the problematic Coldrif syrup batch has been suspended in India — Kerala, although officials confirmed it was not sold there. The move comes after 14 children died in Chhindwara, India — Madhya Pradesh, from suspected renal failure linked to a 'toxic' cough syrup.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard